The US FDA's approval of the novel antibiotic Zaynich, discovered and developed in India, marks a major shift for the Indian pharmaceutical sector. It moves beyond generic manufacturing to showcase high-risk drug discovery capabilities. This is crucial as India bears a disproportionate burden of Antimicrobial Resistance (AMR), and the drug's development used data from Indian healthcare settings.
Exam Lens
Quick Exam Facts From News
1-Minute Revision
- ›Novel Antibiotic: Zaynich
- ›Approving Authority: US FDA
- ›Target this Data: Name of the antibiotic - 'Zaynich'.
- ›Target this Nodal Body: The approving international regulator - 'US FDA' and the suggested Indian regulator - 'Central Drugs Standard Control Organisation (CDSCO)'.
- ›Target this Concept: The global health threat addressed - 'Antimicrobial Resistance (AMR)'.
Mastered this topic? Test your knowledge with a full MCQ quiz.
Practice exam-style questions, track your score, and strengthen your recall.